A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Anatomic Stage IV Breast Cancer AJCC v8 · Metastatic HER2-Negative Breast Carcinoma · Metastatic Hormone Receptor-Positive Breast Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Contact: Study coordinator (Research Coordinator(s) · cvitrial@uw.edu · 866-932-8588
Contact: Principal Investigator (Natasha Hunter, MD)

Study leads

Natasha Hunter, MD
Principal Investigator
Fred Hutch/University of Washington Cancer Consortium

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 · Anatomic Stage IV Breast Cancer AJCC v8 · Locally Advanced Unresectable HER2-Negative Breast Carcinoma

Abroad (travel likely)RecruitingPHASE2

St Louis, United States · Seattle, United States

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Anatomic Stage IV Breast Cancer AJCC v8 · Clinical Stage IV Cutaneous Melanoma AJCC v8 · Locally Advanced Cutaneous Melanoma

Abroad (travel likely)RecruitingPHASE1

Seattle, United States

Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 · Anatomic Stage II Breast Cancer AJCC v8 · Anatomic Stage III Breast Cancer AJCC v8

Abroad (travel likely)RecruitingPHASE2

Scottsdale, United States

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 · HER2-Negative Breast Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Columbus, United States